SELB Lots Of Technical Levels To Look At
$NASDAQ:SELB filled that gap down from its data miss a few weeks back and now testing a pretty consistent level of previous support/resistance.
"Selecta and IGAN Biosciences entered into a research license and option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A protease for the treatment of IgA Nephropathy. We then saw the company and AskBio receive FDA Rare Pediatric Disease Designation for their gene therapy for methylmalonic Acidemia; several key milestones in a very short time span...Director Timothy Springer remains bullish on the company. He picked up another 3.6 million shares from October 21-23 at prices ranging from $2.4994 to $2.7147. Springer has been buying up shares for weeks. This latest round brings his position size to over 11 million shares in the company so far."
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
"Selecta and IGAN Biosciences entered into a research license and option agreement to study Selecta’s ImmTOR™ immune tolerance platform in combination with IGAN’s immunoglobulin A protease for the treatment of IgA Nephropathy. We then saw the company and AskBio receive FDA Rare Pediatric Disease Designation for their gene therapy for methylmalonic Acidemia; several key milestones in a very short time span...Director Timothy Springer remains bullish on the company. He picked up another 3.6 million shares from October 21-23 at prices ranging from $2.4994 to $2.7147. Springer has been buying up shares for weeks. This latest round brings his position size to over 11 million shares in the company so far."
Original Quote Source: 5 Biotech Penny Stocks To Watch With Recent & Upcoming Events
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.